New York-based UTR Therapeutics Inc (UTRx) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for UTRxM1-18, a novel therapeutic approach targeting c-MYC driven cancers. The submission marks a significant milestone for the company's proprietary 3'UTR engineering platform, which precisely targets and degrades specific disease-causing transcripts.
UTRxM1-18 represents a potentially groundbreaking approach to addressing one of oncology's most challenging targets. The c-MYC oncogene is overexpressed in more than 75% of human cancers, but previous therapeutic attempts have been hampered by off-target effects and toxicity concerns.
Novel Mechanism of Action
The investigational therapy employs UTR's proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with high precision. Pioneered by Dr. Chidiebere Awah, CEO and Principal Investigator at UTRx, the technology recognizes specific motifs and reprograms ribosome machinery from translation to degradation, utilizing molecular machinery found exclusively in tumor cells.
"This IND submission is a seismic leap forward and offers patients an option where there are none," said Dr. Awah. "Our technology's unique ability to therapeutically degrade mRNA transcripts redefines what's possible in biotech."
This selective mechanism results in targeted destruction of c-MYC in cancer cells while demonstrating excellent safety profiles in normal cells, addressing a key challenge that has historically limited c-MYC-directed therapies.
Promising Preclinical Data
In animal studies, UTRxM1-18 demonstrated robust dose-dependent efficacy against human-derived tumors from multiple cancer subtypes, including triple negative breast cancer, pancreatic cancer, colorectal cancer, and ovarian cancer. Importantly, researchers observed no dose-limiting toxicities even at the highest doses tested, suggesting a potentially favorable safety profile.
Dr. Kevin Struhl, co-inventor of the technology, advisor to UTRx, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard University, noted: "The validation data supports the technological abilities of engineering mRNA stability elements on the 3'UTR of oncogenes for therapeutic use."
Clinical Development Timeline
Pending FDA approval of the IND application, UTRx anticipates initiating a first-in-human Phase 1 clinical trial in 2026. The trial will evaluate UTRxM1-18 in patients with c-MYC driven tumors, focusing on the four cancer types that showed promising responses in preclinical studies.
Dr. David T. Asuzu, Chief Medical Officer for Adult Cancers at UTRx, emphasized the transformative potential of the approach: "We're not just innovating—we're rewriting the future of cancer and disease."
Broader Pipeline and Platform Potential
Founded in 2021, UTR Therapeutics has developed a portfolio of drug candidates leveraging its 3'UTR engineering platform and proprietary IO Nanocage Delivery System. Beyond UTRxM1-18, the company's pipeline includes therapies targeting MYCN for childhood and adult cancers, TEAD1 and YAP1 for various cancer types, and additional candidates for obesity, metabolic dysfunction-associated steatohepatitis (MASH), and neurodegenerative diseases.
The company's technology platform represents a novel approach to targeting previously "undruggable" disease drivers by manipulating RNA stability rather than focusing on protein inhibition, potentially opening new avenues for therapeutic intervention across multiple disease areas.
Market and Investment Implications
UTRx is actively seeking partnerships to advance its pipeline through clinical development. The company has indicated openness to both institutional and retail investors, highlighting "unique investment vehicles" for the latter group.
If successful in clinical development, UTRxM1-18 could address significant unmet needs across multiple difficult-to-treat cancers. The c-MYC oncogene has long been recognized as a critical driver of malignancy, but its role as a transcription factor has made it challenging to target with conventional therapeutic approaches.
The IND submission represents an important regulatory step toward clinical validation of UTR's platform technology, with potential implications extending beyond the lead candidate to the company's broader pipeline of RNA-targeting therapeutics.
